EGFR and non-small cell lung carcinoma: Dacomitinib, another pan-HER kinase inhibitor, significantly prolonged PFS for patients with EGFR-mutated NSCLC, compared to gefitinib (mPFS, 14.7 months vs. 9.2 months; hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.47–0.74; p < 0.0001) [42].